Cardiovascular Disease and Primary Ovarian Insufficiency

ABSTRACT

Cardiovascular disease (CVD) is the number-one killer of women. Women with primary ovarian insufficiency (POI) may be more burdened by cardiovascular disease, such as myocardial infarction and stroke, as compared with women with normal menopause. The increased burden may be mediated by a worsening of cardiovascular risk factors, such as lipids, corresponding with the loss of ovarian function. In contrast, the increased burden may be caused by factors that precede and potentially contribute to both CVD events and ovarian decline, such as X-chromosome abnormalities and smoking. Regardless of the cause, women with POI may serve as an important population to target for CVD screening and prevention strategies. These strategies should include the use of CVD risk stratification tools to identify women that may benefit from lifestyle modification and pharmacological therapy to prevent CVD. Sex steroid therapy for the sole purpose of CVD prevention in women with POI cannot be recommended, based on a lack of evidence.

KEYWORDS

POI - MI - stroke - heart disease - cardiovascular disease

REFERENCES

• 1 Leading causes of death in females, United States, 2006. Atlanta, GA: Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/women/lcod/ Accessed July 27, 2010
• 2 Amagai Y, Ishikawa S, Gotoh T, Kayaba K, Nakamura Y, Kajii E. Age at menopause and mortality in Japan: the Jichi Medical School Cohort Study.  J Epidemiol. 2006;  16 (4) 161-166
• 3 Kannel W B, Hjortland M C, McNamara P M, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study.  Ann Intern Med. 1976;  85 (4) 447-452
• 4 Atsma F, Bartelink M L, Grobbee D E, van der Schouw Y T. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis.  Menopause. 2006;  13 (2) 265-279
• 5 Luborsky J L, Meyer P, Sowers M F, Gold E B, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition.  Hum Reprod. 2003;  18 (1) 199-206
• 6 Rebar R W, Connolly H V. Clinical features of young women with hypergonadotropic amenorrhea.  Fertil Steril. 1990;  53 (5) 804-810
• 7 Murabito J M, Yang Q, Fox C, Wilson P W, Cupples L A. Heritability of age at natural menopause in the Framingham Heart Study.  J Clin Endocrinol Metab. 2005;  90 (6) 3427-3430
• 8 Nelson L M. Clinical practice. Primary ovarian insufficiency.  N Engl J Med. 2009;  360 (6) 606-614
• 9 Gravholt C H. Epidemiological, endocrine and metabolic features in Turner syndrome.  Eur J Endocrinol. 2004;  151 (6) 657-687
• 10 Bondy C A. Turner Syndrome Study Group . Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group.  J Clin Endocrinol Metab. 2007;  92 (1) 10-25
• 11 Snowdon D A, Kane R L, Beeson W L et al. Is early natural menopause a biologic marker of health and aging?.  Am J Public Health. 1989;  79 (6) 709-714
• 12 Snowdon D A. Early natural menopause and the duration of postmenopausal life. Findings from a mathematical model of life expectancy.  J Am Geriatr Soc. 1990;  38 (4) 402-408
• 13 Cooper G S, Sandler D P. Age at natural menopause and mortality.  Ann Epidemiol. 1998;  8 (4) 229-235
• 14 Cooper G S, Baird D D, Weinberg C R, Ephross S A, Sandler D P. Age at menopause and childbearing patterns in relation to mortality.  Am J Epidemiol. 2000;  151 (6) 620-623
• 15 Jacobsen B K, Heuch I, Kvåle G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women.  Am J Epidemiol. 2003;  157 (10) 923-929
• 16 Jacobsen B K, Nilssen S, Heuch I, Kvåle G. Does age at natural menopause affect mortality from ischemic heart disease?.  J Clin Epidemiol. 1997;  50 (4) 475-479
• 17 van der Schouw Y T, van der Graaf Y, Steyerberg E W, Eijkemans J C, Banga J D. Age at menopause as a risk factor for cardiovascular mortality.  Lancet. 1996;  347 (9003) 714-718
• 18 Jacobsen B K, Knutsen S F, Fraser G E. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study.  J Clin Epidemiol. 1999;  52 (4) 303-307
• 19 Schoemaker M J, Swerdlow A J, Higgins C D, Wright A F, Jacobs P A. United Kingdom Clinical Cytogenetics Group . Mortality in women with Turner syndrome in Great Britain: a national cohort study.  J Clin Endocrinol Metab. 2008;  93 (12) 4735-4742
• 20 Gravholt C H, Juul S, Naeraa R W, Hansen J. Morbidity in Turner syndrome.  J Clin Epidemiol. 1998;  51 (2) 147-158
• 21 Oliver M F. Ischaemic heart disease in young women.  BMJ. 1974;  4 (5939) 253-259
• 22 Gordon T, Kannel W B, Hjortland M C, McNamara P M. Menopause and coronary heart disease. The Framingham Study.  Ann Intern Med. 1978;  89 (2) 157-161
• 23 Rosenberg L, Hennekens C H, Rosner B, Belanger C, Rothman K J, Speizer F E. Early menopause and the risk of myocardial infarction.  Am J Obstet Gynecol. 1981;  139 (1) 47-51
• 24 Kannel W B. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study.  Am Heart J. 1987;  114 (2) 413-419
• 25 Gold E B, Bromberger J, Crawford S et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women.  Am J Epidemiol. 2001;  153 (9) 865-874
• 26 Hu F B, Grodstein F, Hennekens C H et al. Age at natural menopause and risk of cardiovascular disease.  Arch Intern Med. 1999;  159 (10) 1061-1066
• 27 Løkkegaard E, Jovanovic Z, Heitmann B L, Keiding N, Ottesen B, Pedersen A T. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy.  Maturitas. 2006;  53 (2) 226-233
• 28 Jacobsen B K, Heuch I, Kvåle G. Age at natural menopause and stroke mortality: cohort study with 3561 stroke deaths during 37-year follow-up.  Stroke. 2004;  35 (7) 1548-1551
• 29 Baba Y, Ishikawa S, Amagi Y et al.. Premature menopause is associated with increased risk of cerebral infarction in Japanese women.  Menopause. 2010;  17 506-510
• 30 Lisabeth L D, Beiser A S, Brown D L, Murabito J M, Kelly-Hayes M, Wolf P A. Age at natural menopause and risk of ischemic stroke: the Framingham heart study.  Stroke. 2009;  40 (4) 1044-1049
• 31 Kok H S, van Asselt K M, van der Schouw Y T et al. Heart disease risk determines menopausal age rather than the reverse.  J Am Coll Cardiol. 2006;  47 (10) 1976-1983
• 32 Bittner V. Menopause and cardiovascular risk cause or consequence?.  J Am Coll Cardiol. 2006;  47 (10) 1984-1986
• 33 Matthews K A, Crawford S L, Chae C U et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?.  J Am Coll Cardiol. 2009;  54 (25) 2366-2373
• 34 Akahoshi M, Soda M, Nakashima E et al. Effects of age at menopause on serum cholesterol, body mass index, and blood pressure.  Atherosclerosis. 2001;  156 (1) 157-163
• 35 Landin-Wilhelmsen K, Bryman I, Wilhelmsen L. Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome.  J Clin Endocrinol Metab. 2001;  86 (9) 4166-4170
• 36 Kaufman D W, Slone D, Rosenberg L, Miettinen O S, Shapiro S. Cigarette smoking and age at natural menopause.  Am J Public Health. 1980;  70 (4) 420-422
• 37 Willett W, Stampfer M J, Bain C et al. Cigarette smoking, relative weight, and menopause.  Am J Epidemiol. 1983;  117 (6) 651-658
• 38 Brambilla D J, McKinlay S M. A prospective study of factors affecting age at menopause.  J Clin Epidemiol. 1989;  42 (11) 1031-1039
• 39 van Noord P A, Dubas J S, Dorland M, Boersma H, te Velde E. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors.  Fertil Steril. 1997;  68 (1) 95-102
• 40 Cooper G S, Sandler D P, Bohlig M. Active and passive smoking and the occurrence of natural menopause.  Epidemiology. 1999;  10 (6) 771-773
• 41 McKinlay S M, Bifano N L, McKinlay J B. Smoking and age at menopause in women.  Ann Intern Med. 1985;  103 (3) 350-356
• 42 Akahoshi M, Soda M, Nakashima E, Shimaoka K, Seto S, Yano K. Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index.  Circulation. 1996;  94 (1) 61-66
• 43 Hjortland M C, McNamara P M, Kannel W B. Some atherogenic concomitants of menopause: The Framingham Study.  Am J Epidemiol. 1976;  103 (3) 304-311
• 44 van Beresteijn E C, Korevaar J C, Huijbregts P C, Schouten E G, Burema J, Kok F J. Perimenopausal increase in serum cholesterol: a 10-year longitudinal study.  Am J Epidemiol. 1993;  137 (4) 383-392
• 45 Bittner V. Perspectives on dyslipidemia and coronary heart disease in women.  J Am Coll Cardiol. 2005;  46 (9) 1628-1635
• 46 Do K A, Green A, Guthrie J R, Dudley E C, Burger H G, Dennerstein L. Longitudinal study of risk factors for coronary heart disease across the menopausal transition.  Am J Epidemiol. 2000;  151 (6) 584-593
• 47 Matthews K A, Meilahn E, Kuller L H, Kelsey S F, Caggiula A W, Wing R R. Menopause and risk factors for coronary heart disease.  N Engl J Med. 1989;  321 (10) 641-646
• 48 Matthews K A, Wing R R, Kuller L H, Meilahn E N, Plantinga P. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women.  Arch Intern Med. 1994;  154 (20) 2349-2355
• 49 Chu M C, Rath K M, Huie J, Taylor H S. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk.  Hum Reprod. 2003;  18 (8) 1570-1573
• 50 Taylor H S. Genetic vs hormonal factors in lipid metabolism in women.  JAMA. 2004;  291 (4) 424-425 author reply 425
• 51 Knauff E A, Westerveld H E, Goverde A J et al. Lipid profile of women with premature ovarian failure.  Menopause. 2008;  15 (5) 919-923
• 52 Van P L, Bakalov V K, Bondy C A. Monosomy for the X-chromosome is associated with an atherogenic lipid profile.  J Clin Endocrinol Metab. 2006;  91 (8) 2867-2870
• 53 Cooley M, Bakalov V, Bondy C A. Lipid profiles in women with 45,X vs 46,XX primary ovarian failure.  JAMA. 2003;  290 (16) 2127-2128
• 54 Di Angelantonio E, Sarwar N, Perry P Emerging Risk Factors Collaboration et al. Major lipids, apolipoproteins, and risk of vascular disease.  JAMA. 2009;  302 (18) 1993-2000
• 55 Cui Y, Blumenthal R S, Flaws J A et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality.  Arch Intern Med. 2001;  161 (11) 1413-1419
• 56 Bass K M, Newschaffer C J, Klag M J, Bush T L. Plasma lipoprotein levels as predictors of cardiovascular death in women.  Arch Intern Med. 1993;  153 (19) 2209-2216
• 57 Stampfer M J, Colditz G A, Willett W C et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study.  N Engl J Med. 1991;  325 (11) 756-762
• 58 Hsia J, Criqui M H, Herrington D M Women's Health Initiative Research Group et al. Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative.  Am Heart J. 2006;  152 (1) 170-176
• 59 Rossouw J E, Cushman M, Greenland P et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy.  Arch Intern Med. 2008;  168 (20) 2245-2253
• 60 Anderson G L, Limacher M, Assaf A R Women's Health Initiative Steering Committee et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.  JAMA. 2004;  291 (14) 1701-1712
• 61 Rossouw J E, Anderson G L, Prentice R L Writing Group for the Women's Health Initiative Investigators et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288 (3) 321-333
• 62 Wassertheil-Smoller S, Hendrix S L, Limacher M WHI Investigators et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.  JAMA. 2003;  289 (20) 2673-2684
• 63 López-López R, Huerta R, Malacara J M. Age at menopause in women with type 2 diabetes mellitus.  Menopause. 1999;  6 (2) 174-178
• 64 Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam G, eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific; 1992: 377-384
• 65 Rotterdam ESHRE/ASRM -Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.  Fertil Steril. 2004;  81 (1) 19-25
• 66 Legro R S. A 27-year-old woman with a diagnosis of polycystic ovary syndrome.  JAMA. 2007;  297 (5) 509-519
• 67 Rebar R, Judd H L, Yen S S, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.  J Clin Invest. 1976;  57 (5) 1320-1329
• 68 Hudecova M, Holte J, Olovsson M, Sundström Poromaa I. Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve.  Hum Reprod. 2009;  24 (5) 1176-1183
• 69 Carr M C. The emergence of the metabolic syndrome with menopause.  J Clin Endocrinol Metab. 2003;  88 (6) 2404-2411
• 70 Kim T J, Anasti J N, Flack M R, Kimzey L M, Defensor R A, Nelson L M. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure.  Obstet Gynecol. 1997;  89 (5 Pt 1) 777-779
• 71 Harris M I, Flegal K M, Cowie C C et al.. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994.  Diabetes Care. 1998;  21 518-524
• 72 Bakalov V K, Cheng C, Zhou J, Bondy C A. X-chromosome gene dosage and the risk of diabetes in Turner syndrome.  J Clin Endocrinol Metab. 2009;  94 (9) 3289-3296
• 73 Vaccarino V, Horwitz R I, Meehan T P, Petrillo M K, Radford M J, Krumholz H M. Sex differences in mortality after myocardial infarction: evidence for a sex-age interaction.  Arch Intern Med. 1998;  158 (18) 2054-2062
• 74 Vaccarino V, Parsons L, Every N R, Barron H V, Krumholz H M. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants.  N Engl J Med. 1999;  341 (4) 217-225
• 75 Vaccarino V, Krumholz H M, Yarzebski J, Gore J M, Goldberg R J. Sex differences in 2-year mortality after hospital discharge for myocardial infarction.  Ann Intern Med. 2001;  134 (3) 173-181
• 76 MacIntyre K, Stewart S, Capewell S et al. Gender and survival: a population-based study of 201,114 men and women following a first acute myocardial infarction.  J Am Coll Cardiol. 2001;  38 (3) 729-735
• 77 Vaccarino V, Parsons L, Peterson E D, Rogers W J, Kiefe C I, Canto J. Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006.  Arch Intern Med. 2009;  169 (19) 1767-1774
• 78 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  JAMA. 2001;  285 (19) 2486-2497
• 79 Grundy S M, Cleeman J I, Merz C N Coordinating Committee of the National Cholesterol Education Program et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.  J Am Coll Cardiol. 2004;  44 (3) 720-732
• 80 Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).  JAMA. 1993;  269 (23) 3015-3023
• 81 Ridker P M, Buring J E, Rifai N, Cook N R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.  JAMA. 2007;  297 (6) 611-619
• 82 Mosca L. Guidelines for prevention of cardiovascular disease in women: a summary of recommendations.  Prev Cardiol. 2007;  10 (Suppl 4) 19-25
• 83 Baigent C, Keech A, Kearney P M Cholesterol Treatment Trialists' (CTT) Collaborators et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.  Lancet. 2005;  366 (9493) 1267-1278
• 84 Kearney P M, Blackwell L, Collins R Cholesterol Treatment Trialists' (CTT) Collaborators et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.  Lancet. 2008;  371 (9607) 117-125
• 85 Grundy S M. Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes.  BMJ. 2007;  334 (7601) 982
• 86 Kendrick M. Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No.  BMJ. 2007;  334 (7601) 983
• 87 Abramson J, Wright J M. Are lipid-lowering guidelines evidence-based?.  Lancet. 2007;  369 (9557) 168-169
• 88 Walsh J M, Pignone M. Drug treatment of hyperlipidemia in women.  JAMA. 2004;  291 (18) 2243-2252
• 89 Kenis I, Tartakover-Matalon S, Cherepnin N et al. Simvastatin has deleterious effects on human first trimester placental explants.  Hum Reprod. 2005;  20 (10) 2866-2872
• 90 Edison R J, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure.  N Engl J Med. 2004;  350 (15) 1579-1582
• 91 North American Menopause Society . Estrogen and progestogen use in postmenopausal women: 2010 position statement of the North American Menopause Society.  Menopause. 2010;  17 (2) 242-255
• 92 Santen R J, Allred D C, Ardoin S P Endocrine Society et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement.  J Clin Endocrinol Metab. 2010;  95 (7, Suppl 1) s1-s66
• 93 Langrish J P, Mills N L, Bath L E et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure.  Hypertension. 2009;  53 (5) 805-811
• 94 Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.  Contraception. 2000;  62 (1) 29-38
• 95 Benetti-Pinto C L, Bedone A J, Magna L A. Evaluation of serum androgen levels in women with premature ovarian failure.  Fertil Steril. 2005;  83 (2) 508-510
• 96 Kalantaridou S N, Calis K A, Vanderhoof V H et al. Testosterone deficiency in young women with 46,XX spontaneous premature ovarian failure.  Fertil Steril. 2006;  86 (5) 1475-1482
• 97 Liu P Y, Death A K, Handelsman D J. Androgens and cardiovascular disease.  Endocr Rev. 2003;  24 (3) 313-340
• 98 Flöter A, Nathorst-Böös J, Carlström K, von Schoultz B. Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy.  Maturitas. 2004;  47 (2) 123-129
• 99 Zang H, Carlström K, Arner P, Hirschberg A L. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women.  Fertil Steril. 2006;  86 (1) 136-144
• 100 Diamond M P, Grainger D, Diamond M C, Sherwin R S, Defronzo R A. Effects of methyltestosterone on insulin secretion and sensitivity in women.  J Clin Endocrinol Metab. 1998;  83 (12) 4420-4425
• 101 Kalantaridou S N, Calis K A, Mazer N A, Godoy H, Nelson L M. A pilot study of an investigational testosterone transdermal patch system in young women with spontaneous premature ovarian failure.  J Clin Endocrinol Metab. 2005;  90 (12) 6549-6552
• 102 Chobanian A V, Bakris G L, Black H R National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.  JAMA. 2003;  289 (19) 2560-2572
• 103 Bondy C, Bakalov V K, Lange E D, Ceniceros I. Deficient medical care for adults with the Turner syndrome.  Ann Intern Med. 2006;  145 (11) 866-867
• 104 Gravholt C H. Medical problems of adult Turner's syndrome.  Horm Res. 2001;  56 (Suppl 1) 44-50
• 105 Wiggins D A, Main E. Outcomes of pregnancies achieved by donor egg in vitro fertilization—a comparison with standard in vitro fertilization pregnancies.  Am J Obstet Gynecol. 2005;  192 (6) 2002-2006 discussion 2006-2008
• 106 Söderström-Anttila V, Tiitinen A, Foudila T, Hovatta O. Obstetric and perinatal outcome after oocyte donation: comparison with in-vitro fertilization pregnancies.  Hum Reprod. 1998;  13 (2) 483-490
• 107 Pados G, Camus M, Van Steirteghem A, Bonduelle M, Devroey P. The evolution and outcome of pregnancies from oocyte donation.  Hum Reprod. 1994;  9 (3) 538-542
• 108 Practice Committee of American Society for Reproductive Medicine . Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome.  Fertil Steril. 2008;  90 (5, Suppl) S185-S186
• 109 Hiratzka L F, Bakris G L, Beckman J A American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine.  J Am Coll Cardiol. 2010;  55 (14) e27-e129
• 110 National Heart, Lung and Blood Institute, National Institutes of Health .Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Risk Assessment Tool for Estimating Your 10-year Risk of Having a Heart Attack. Available at: http://hp2010.nhlbihin.net/atpiii/calculator.asp Accessed November 3, 2010